8-K: Opus Genetics Reports Positive Phase 1/2 Data for OPGx-BEST1

Opus Genetics announced positive low-dose Cohort 1 data from its Phase 1/2 trial of OPGx-BEST1 for BEST1-related retinal diseases, showing clinically meaningful improvements in visual function and structural changes, alongside a favorable safety profile.

Summary

• Opus Genetics presented 3and 6-month results from Cohort 1 of its Phase 1/2 clinical trial for OPGx-BEST1, a gene therapy for BEST1-related retinal diseases like BVMD and ARB.
• All five participants in Cohort 1 (treated at 1.5 x 10^9 vg/eye) showed clinically meaningful improvements in visual function, with four also demonstrating structural improvements.
• The therapy demonstrated a favorable safety and tolerability profile, with no serious adverse events or dose-limiting toxicities.
• Best-corrected visual acuity (BCVA) improved in 60% (3/5) of participants, low-luminance visual acuity (LLVA) in 40% (2/5), and contrast sensitivity in 40% (2/5).
• Microperimetry showed a clinically meaningful improvement in retinal sensitivity in 75% (3/4) of evaluable participants, concentrated in the treated retinal pigment epithelial (RPE) Transitional Zone.
• Structural improvements included reductions in vitelliform material in 67% of BVMD participants (2/3) and intraretinal fluid in 100% of ARB participants (2/2).
• The company has advanced to Cohort 2, evaluating a higher dose (4.5 x 10^9 vg/eye), with dosing expected to complete in Q4 2026 and topline data in Q2 2027.
• Opus Genetics met with the FDA and aligned on a potential pivotal trial endpoint: a 3 dB microperimetry improvement in 5 prespecified loci, combined with a patient-reported outcome.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with encouraging clinical data and regulatory alignment, suggesting a promising path forward for the OPGx-BEST1 therapy.

Positives

• All five participants in Cohort 1 demonstrated clinically meaningful improvement in visual function.
• Four out of five participants showed structural improvements.
• OPGx-BEST1 exhibited a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities.
• 60% of participants showed improvement in best-corrected visual acuity (BCVA).
• 75% of evaluable participants demonstrated clinically meaningful improvement in retinal sensitivity via microperimetry.
• Structural improvements included reductions in vitelliform material in BVMD patients and intraretinal fluid in ARB patients.
• The company aligned with the FDA on a potential pivotal trial endpoint, streamlining future development.
• Cohort 2 has been over-enrolled, indicating strong interest and progress in the higher-dose study.

Negatives

• The greatest functional improvements were observed in participants with less advanced disease, suggesting potential limitations in treating more advanced stages.
• One BVMD participant showed only possible, not definitive, reduction in vitelliform material.
• The clinical trial data is interim and subject to change as more data becomes available.
• The company has not generated significant revenue and expects to incur losses for the foreseeable future.

Risks

• The results of preclinical studies or clinical trials may not be predictive of future results.
• Uncertainty regarding the timing and results of regulatory submissions.
• Potential delays or failure to obtain clearance for Investigational New Drug Applications, New Drug Applications, or other global regulatory submissions.
• Risks related to the company's ability to protect and maintain its intellectual property.
• Risks related to manufacturing, supply, and distribution of product candidates.
• The interim results may not be predictive of final clinical trial results.
• The company's future viability is difficult to assess due to its short operating history and need for substantial additional capital.
• Reliance on third parties for material aspects of its business, such as clinical trials and manufacturing.

Future Outlook

The company expects to complete dosing for Cohort 2 in Q4 2026, with topline three-month data anticipated in Q2 2027. Planning for participant dosing in the Phase 3 clinical trial is expected to begin in 2027. Commercial manufacturing requirements are expected to be completed in early 2027. The company's current cash runway extends into 2029, supporting multiple clinical programs through critical inflection points.

Management Comments

• These Cohort 1 data provide important evidence of OPGx-BEST1s potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease, which we believe has a significantly larger underserved patient population than we previously thought.
• The functional and structural improvements across Cohort 1, particularly the greater functional gains observed in patients with viable retinal tissue, reinforce our confidence in OPGx-BEST1s potential to have a positive impact on the lives of patients with BEST disease.
• Together with our recent FDA interaction and rapid enrollment of Cohort 2, we believe these data provide a clear path toward pivotal development, which we plan to begin next year.
• We want to recognize the contributions of our investigators, clinical teams, and most importantly, the patients helping advance a potential treatment for this blinding disease.

Industry Context

StockSavvy.ai notes that the positive clinical data and FDA alignment for OPGx-BEST1 position Opus Genetics favorably within the gene therapy sector for inherited retinal diseases, a field with significant unmet needs and growing investment. The expanded patient population estimates also suggest a larger market opportunity than previously anticipated.

Stakeholder Impact

• Shareholders: Positive clinical data and regulatory alignment may lead to increased investor confidence and potential stock price appreciation.
• Patients: The therapy shows promise for treating BEST1-related retinal diseases, offering potential for improved vision and quality of life.
• Medical Community: The results contribute to the growing body of evidence for gene therapy in treating inherited retinal diseases.

Next Steps

• Complete dosing for Cohort 2 of the OPGx-BEST1 Phase 1/2 clinical trial (expected Q4 2026).
• Announce topline three-month data from Cohort 2 (expected Q2 2027).
• Complete Phase 3 and commercial manufacturing requirements (expected early 2027).
• Begin planning for participant dosing in the Phase 3 clinical trial (expected 2027).
• Initiate MERTK clinical study (expected Q4 2026).
• Initiate RDH12 clinical study (expected Q4 2026).
• Initiate LCA5 Phase 3 dosing (expected Oct 2026).

Key Dates

Recommendation

The interim results are encouraging, showing positive safety and efficacy signals, and regulatory alignment is a significant step. However, the data is preliminary, and the company faces substantial risks inherent in clinical development and manufacturing. Further data from Cohort 2 and the pivotal trial are needed to confirm these findings and assess long-term viability. Therefore, a 'hold' recommendation is prudent, pending more definitive results.

Keywords

gene therapy, inherited retinal diseases, BEST1-related retinal diseases, OPGx-BEST1, Best vitelliform macular dystrophy, autosomal recessive bestrophinopathy, clinical trial, ophthalmology